 This is a Bloomberg Money Minute. Now that obesity drug maker Eli Lilly is sitting on a fat pile of cash thanks to hot demand for its Zepbound, it's putting some of that money to work. Lilly is paying $3.2 billion to acquire Morphic Holding. Morphic has a pill being studied in mid-stage clinical trials for treating conditions including ulcerative colitis and Crohn's disease. Its shares are up 75%. Stock in Boeing is finding lift to the tune of about 3% today, even as families of the 300